MBCProject_1160_T2_RNA
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- MYC_TARGETS_V2+0.560
- G2M_CHECKPOINT+0.510
- MYC_TARGETS_V1+0.470
- UNFOLDED_PROTEIN_RESPONSE+0.340
- INTERFERON_ALPHA_RESPONSE+0.330
- GLYCOLYSIS+0.300
- UV_RESPONSE_UP+0.240
- MTORC1_SIGNALING+0.230
- DNA_REPAIR+0.210
Top 10 suppressed
- COAGULATION-0.310
- IL6_JAK_STAT3_SIGNALING-0.310
- IL2_STAT5_SIGNALING-0.290
- BILE_ACID_METABOLISM-0.270
- ANGIOGENESIS-0.260
- UV_RESPONSE_DN-0.260
- ESTROGEN_RESPONSE_EARLY-0.250
- KRAS_SIGNALING_UP-0.230
- ALLOGRAFT_REJECTION-0.220
- MYOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07R-01A-21R-A034-07 | — | E | 0.865 |
| 2 | TCGA-AO-A124-01A-11R-A10J-07 | — | E | 0.862 |
| 3 | 20020093.Her2HRneg | — | E | 0.836 |
| 4 | TCGA-77-7138-01A-41R-2045-07 | — | cohortSQ1 | 0.832 |
| 5 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.830 |
| 6 | SRR8518179 | — | E | 0.829 |
| 7 | SRR23303750 | — | — | 0.827 |
| 8 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.826 |
| 9 | TCGA-CV-6003-01A-11R-1686-07 | — | — | 0.825 |
| 10 | SRR15030853 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |